Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. It is not yet known whether the effectiveness of celecoxib in treating
glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and
undergoing radiation therapy.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are
receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed
glioblastoma multiforme.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins